HALO Precision Diagnostics is partnering with Bayer in the QUANTI Phase III clinical development program for gadoquatrane. This initiative aims to assess the safety and effectiveness of gadoquatrane, an investigational gadolinium-based contrast agent used in MRI. 

HALO’s Indian Wells, California Innovation Center is one of Bayer’s first QUANTI partner sites globally and recently became the first to include a pediatric participant into the gadoquatrane development program.

“Our partnership with Bayer is the latest example of HALO leading the way when it comes to advancements supporting early disease detection,” says Bernadette Greenwood, chief research officer, HALO. “We are grateful to Bayer for its partnership and the opportunity to potentially impact the diagnostic pathway for patients.”

The QUANTI clinical development program consists of three clinical trials:

  1. QUANTI CNS evaluates the efficacy and safety of gadoquatrane in adults with known or highly suspected pathologies of the central nervous system undergoing a contrast-enhanced MRI.
  2. QUANTI OBR investigates the safety and efficacy of gadoquatrane in contrast-enhanced MRI of all other body regions, such as head and neck, thorax, abdomen, pelvis, and extremities.
  3. QUANTI PEDS assesses the pharmacokinetics and safety of gadoquatrane in children aged 0-18 years undergoing contrast-enhanced MRI.

Across the three studies, the QUANTI clinical development program expects to enroll 800 patients across 17 countries.

“We perpetually aim to develop healthcare innovations that support patients and doctors managing health conditions,” adds Marta Santiuste, R&D clinical development head, radiology at Bayer. “We’re very encouraged by the progress of our QUANTI development program and value HALO’s continued partnership and contributions.”

HALO, through a growing network of owned and partner clinics and the company’s proprietary precision diagnostics platform, integrates advanced imaging with molecular diagnostics to deliver comprehensive clinical insights for early disease detection and treatment. The company has clinically validated care pathways for prostate cancer, breast cancer, and cardiovascular disease, as well as plans for neurodegenerative and other life-threatening diseases, HALO officials say.